Botswana is experiencing a growing threat of multidrug/rifampicin resistant tuberculosis in recent years. The inability to rapidly diagnose tuberculosis and associated drug resistance may lead to increased morbidity and mortality in patients as well as the spread of resistant strains of tuberculosis to uninfected population. In response to the long turnaround time inherent with conventional drug susceptibility testing methods, Botswana National Tuberculosis Programme adopted the World Health Organization- endorsed Xpert MTB/RIF for the rapid detection of tuberculosis and drug resistance as an alternative to conventional culture-based drug susceptibility testing. This molecular assay allows for early diagnosis of drug resistance and prompt initiation of appropriate therapy. Therefore the aim of this study was to investigate the potential of Xpert MTB/RIF assay to rapidly diagnose drug resistance in routine clinical practice in Botswana and to compare the cost of detecting multidrug/rifampicin resistance with conventional drug susceptibility testing. The findings of this study are critical for disease control and may complement a well-functioning TB control program.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Botswana is experiencing a growing threat of multidrug/rifampicin resistant tuberculosis in recent years. The inability to rapidly diagnose tuberculosis and associated drug resistance may lead to increased morbidity and mortality in patients as well as the spread of resistant strains of tuberculosis to uninfected population. In response to the long turnaround time inherent with conventional drug susceptibility testing methods, Botswana National Tuberculosis Programme adopted the World Health Organization- endorsed Xpert MTB/RIF for the rapid detection of tuberculosis and drug resistance as an alternative to conventional culture-based drug susceptibility testing. This molecular assay allows for early diagnosis of drug resistance and prompt initiation of appropriate therapy. Therefore the aim of this study was to investigate the potential of Xpert MTB/RIF assay to rapidly diagnose drug resistance in routine clinical practice in Botswana and to compare the cost of detecting multidrug/rifampicin resistance with conventional drug susceptibility testing. The findings of this study are critical for disease control and may complement a well-functioning TB control program. 64 pp. Englisch. N° de réf. du vendeur 9786200500434
Quantité disponible : 2 disponible(s)
Vendeur : Books Puddle, Woodside, NY, Etats-Unis
Etat : New. N° de réf. du vendeur 26387308484
Quantité disponible : 4 disponible(s)
Vendeur : Majestic Books, Hounslow, Royaume-Uni
Etat : New. Print on Demand. N° de réf. du vendeur 392324123
Quantité disponible : 4 disponible(s)
Vendeur : Biblios, Frankfurt am main, HESSE, Allemagne
Etat : New. PRINT ON DEMAND. N° de réf. du vendeur 18387308494
Quantité disponible : 4 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Taschenbuch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Botswana is experiencing a growing threat of multidrug/rifampicin resistant tuberculosis in recent years. The inability to rapidly diagnose tuberculosis and associated drug resistance may lead to increased morbidity and mortality in patients as well as the spread of resistant strains of tuberculosis to uninfected population. In response to the long turnaround time inherent with conventional drug susceptibility testing methods, Botswana National Tuberculosis Programme adopted the World Health Organization- endorsed Xpert MTB/RIF for the rapid detection of tuberculosis and drug resistance as an alternative to conventional culture-based drug susceptibility testing. This molecular assay allows for early diagnosis of drug resistance and prompt initiation of appropriate therapy. Therefore the aim of this study was to investigate the potential of Xpert MTB/RIF assay to rapidly diagnose drug resistance in routine clinical practice in Botswana and to compare the cost of detecting multidrug/rifampicin resistance with conventional drug susceptibility testing. The findings of this study are critical for disease control and may complement a well-functioning TB control program. N° de réf. du vendeur 9786200500434
Quantité disponible : 1 disponible(s)
Vendeur : moluna, Greven, Allemagne
Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Tembo Blackson PitoloDr. Blackson Pitolo Tembo is an accomplished public health specialist working as a consultant / researcher in Zambia. Professor Ntambwe Gustav Malangu was a pharmacoepidemiologist with public health expertise in . N° de réf. du vendeur 385892460
Quantité disponible : Plus de 20 disponibles
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -Botswana is experiencing a growing threat of multidrug/rifampicin resistant tuberculosis in recent years. The inability to rapidly diagnose tuberculosis and associated drug resistance may lead to increased morbidity and mortality in patients as well as the spread of resistant strains of tuberculosis to uninfected population. In response to the long turnaround time inherent with conventional drug susceptibility testing methods, Botswana National Tuberculosis Programme adopted the World Health Organization- endorsed Xpert MTB/RIF for the rapid detection of tuberculosis and drug resistance as an alternative to conventional culture-based drug susceptibility testing. This molecular assay allows for early diagnosis of drug resistance and prompt initiation of appropriate therapy. Therefore the aim of this study was to investigate the potential of Xpert MTB/RIF assay to rapidly diagnose drug resistance in routine clinical practice in Botswana and to compare the cost of detecting multidrug/rifampicin resistance with conventional drug susceptibility testing. The findings of this study are critical for disease control and may complement a well-functioning TB control program.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 64 pp. Englisch. N° de réf. du vendeur 9786200500434
Quantité disponible : 1 disponible(s)
Vendeur : Buchpark, Trebbin, Allemagne
Etat : Sehr gut. Zustand: Sehr gut | Sprache: Englisch | Produktart: Bücher | Botswana is experiencing a growing threat of multidrug/rifampicin resistant tuberculosis in recent years. The inability to rapidly diagnose tuberculosis and associated drug resistance may lead to increased morbidity and mortality in patients as well as the spread of resistant strains of tuberculosis to uninfected population. In response to the long turnaround time inherent with conventional drug susceptibility testing methods, Botswana National Tuberculosis Programme adopted the World Health Organization- endorsed Xpert MTB/RIF for the rapid detection of tuberculosis and drug resistance as an alternative to conventional culture-based drug susceptibility testing. This molecular assay allows for early diagnosis of drug resistance and prompt initiation of appropriate therapy. Therefore the aim of this study was to investigate the potential of Xpert MTB/RIF assay to rapidly diagnose drug resistance in routine clinical practice in Botswana and to compare the cost of detecting multidrug/rifampicin resistance with conventional drug susceptibility testing. The findings of this study are critical for disease control and may complement a well-functioning TB control program. N° de réf. du vendeur 36037897/2
Quantité disponible : 2 disponible(s)